Calliditas Announces Positive NefIgArd Open Label Extension Results
Calliditas Therapeutics AB - American Depositary Shares (CALT)
Company Research
Source: PR Newswire
STOCKHOLM, April 24, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (NASDAQ: CALT), (NASDAQ STOCKHOLM: CALTX) ("Calliditas") today announced that the global open-label extension (OLE) study to the Phase 3 NefIgArd study showed a treatment response consistent with the NefIgArd study across endpoints of urine protein to creatinine ration (UPCR) and estimated glomerular filtration rate (eGFR) at 9 months across all IgAN patients, including those who had previously received Nefecon in the NefIgArd study.NefIgArd was a global, Phase 3, randomized, double-blind, placebo-controlled, multicenter study designed to evaluate the efficacy and safety of Nefecon 16 mg once daily vs placebo in adult patients with primary IgAN as an addition to optimized RASi therapy. Patients were randomized 1:1 to receive 16 mg/day of Nefecon or matching placebo for 9 months, followed by a 15-month observational follow-up period without the study drug. The NefIgArd study achieved both its primary and key secondary
Show less
Read more
Impact Snapshot
Event Time:
CALT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CALT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CALT alerts
High impacting Calliditas Therapeutics AB - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
CALT
News
- Three Swedish Growth Companies With High Insider Ownership And Up To 53% Earnings Growth [Yahoo! Finance]Yahoo! Finance
- Calliditas Therapeutics' 2023 Annual Report PublishedPR Newswire
- Calliditas Therapeutics' 2023 Annual Report Published [Yahoo! Finance]Yahoo! Finance
- Calliditas Therapeutics' 2023 Annual Report PublishedPR Newswire
- Calliditas Announces Positive NefIgArd Open Label Extension Results [Yahoo! Finance]Yahoo! Finance
CALT
Analyst Actions
- 2/22/24 - HC Wainwright
CALT
Sec Filings
- 4/25/24 - Form 6-K
- 4/24/24 - Form 20-F
- 3/6/24 - Form 6-K
- CALT's page on the SEC website